Last updated 4 days ago
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
320 patients around the world
Available in United States, Argentina
Genentech, Inc.
15Research sites
320Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
Recruiting
Centro Médico Privado CEMAIC - Córdoba
Recruiting
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
Hospital Provincial del Centenario - Rosario, Santa Fe
Recruiting
Organización Médica de Investigación (OMI)
Recruiting
Centro Oncológico de Integración Regional C.O.I.R.
Recruiting
Instituto de Oncología Ángel H. Roffo - CABA, Buenos Aires
Recruiting
Instituto de Oncología de Rosario - IOR
Recruiting
Consultorios Médicos Dr. Doreski
Recruiting
Fundación CENIT para la Investigación en Neurociencias
Recruiting
StudyevERA
SponsorGenentech, Inc.
Conditions
Breast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05306340
